Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
iwCLL 2021
It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸
Click here to watch: 👉
#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...
ow.ly
In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.
Watch it here: 👉
#MMSM #Myeloma
Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis
Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...
ow.ly
🚨On December 23, 2025, the FDA approved mitapivat for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, based on data from the ENERGIZE & ENERGIZE-T trials.
Find out more about the approval here:
🗞️ 👉 https://ow.ly/gohh50XRPCq
Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸
Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:
👉 👈
#CLLsm #Leusm #CTSM
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...
ow.ly
We recently caught up with the lovely @mbeksac56 of @istinyeunivedu, who discussed a subgroup analysis of the DREAMM-7 & DREAMM-8 trials, evaluating outcomes with belantamab mafodotin in functional high-risk R/R #MultipleMyeloma.
Watch here: 👉
#MMSM
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses a subgroup analysis of the DREAMM-...
ow.ly
iwCLL 2021
It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸
Click here to watch: 👉
#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM
A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL
Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...
ow.ly
In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.
Watch it here: 👉
#MMSM #Myeloma
Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis
Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...
ow.ly
🚨On December 23, 2025, the FDA approved mitapivat for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, based on data from the ENERGIZE & ENERGIZE-T trials.
Find out more about the approval here:
🗞️ 👉 https://ow.ly/gohh50XRPCq
Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸
Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:
👉 👈
#CLLsm #Leusm #CTSM
huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure
Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...
ow.ly
We recently caught up with the lovely @mbeksac56 of @istinyeunivedu, who discussed a subgroup analysis of the DREAMM-7 & DREAMM-8 trials, evaluating outcomes with belantamab mafodotin in functional high-risk R/R #MultipleMyeloma.
Watch here: 👉
#MMSM
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses a subgroup analysis of the DREAMM-...
ow.ly
